Immunotherapy cocktail aims to shrink head and neck tumors before surgery
NCT ID NCT07371897
First seen Feb 01, 2026 · Last updated Jun 20, 2026 · Updated 22 times
Summary
This study tests whether adding chemotherapy to the immunotherapy drug toripalimab before surgery helps keep head and neck cancer from coming back. About 154 adults with advanced but operable cancer will get either toripalimab alone or with chemo for two cycles, then have surgery and radiation. The goal is to see which approach leads to longer cancer-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (immunotherapy) with or without docetaxel and cisplatin (chemotherapy)
What this could lead to
If successful, this could offer a more effective pre-surgery treatment to lower the chance of head and neck cancer returning.
What could go wrong
This is an early-stage Phase 3 trial with only 154 participants. The added chemo may increase side effects without improving outcomes, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.